Medicaid
Prescription Drug Coverage 04/12/2021 Revised 03/29/2022 Revised | AMCP supports the inclusion of prescription drug coverage in all health care benefit programs, including those administered by the government (e.g., Medicare, Medicaid, health insurance exchanges). Access to and proper utilization of a comprehensive prescription drug benefit, have been shown to reduce the severity of and complications arising from many common illnesses. Failure to provide prescription drug coverage can increase the use of more intensive, costly health care services, such as surgery and/or hospitalization. AMCP also supports granting flexibility to managed care organizations to develop clinically sound, evidence-based benefits free from arduous mandates. (See AMCP Managed Care Pharmacy Practice Positions - Prescription Drug Coverage) |
Government-Mandated Pharmacy Benefits 02/13/2019 Reapproved | AMCP supports the right of managed care organizations and their clients to independently make decisions with regard to health benefits that meet the medical needs of specific patient populations while being compassionate, medically sound, timely, and fiscally responsible. Federal and state legislation and regulations should not hinder a health care delivery system's ability to provide customized benefits that assure value and quality patient care for specific patient populations, yet remain affordable. |
Patient Satisfaction 04/07/2015 Reapproved | AMCP supports the development of mechanisms that measure the level of satisfaction patients have with pharmacy services. Acquired data may be used for quality improvement efforts, to increase public recognition of pharmacy services, monitor trends, benchmark improvement efforts, and establish the value of the array of pharmacy services to all stakeholders. |
| Best Price Requirements of the Medicaid Drug Rebate Program Policy 0904 06/01/2009 Introduced | AMCP believes that the best price provisions of the Medicaid prescription drug rebate program, established by the Omnibus Budget Reconciliation Act of 1990 (P.L. 101-508), represents interference by the government into the competitive marketplace that has raised costs unnecessarily by preventing the commercial market from allowing true market dynamics to emerge. This pernicious market effect has been well documented by the U.S. Government Accountability Office (GAO), the Congressional Budget Office (CBO) and academic economists. AMCP strongly encourages a careful re-examination of the best price program.
|
Government Regulation of Prescription Drug Prices 04/12/2021 Revised | AMCP believes that government regulation of prescription drug pricing could result in unintended consequences such as higher costs for patients, payers, and providers. Government-regulated prices could greatly impair the ability of managed care organizations (MCOs) to design a competitive benefit offering that integrates clinically sound, evidence-based medication choices with delivery systems and co-payment alternatives that provide beneficiaries with substantive choice. AMCP works to ensure patient access to medications at an affordable cost and supports working with elected officials and health care stakeholders to develop practical, informed, and market-based solutions to make prescription drugs more affordable and accessible. (See AMCP Managed Care Pharmacy Practice Positions - Government Regulation of Prescription Drug Prices) |
Featured News & Resources
See Full CalendarNews & Resources by Topic
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
